The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients - Latva-Rasku, A; Honka, M J; Kullberg, J (Diabetes Care, 2019)